Melioidosis is an emerging, potentially fatal disease caused by Gram-negative saprophytic bacterium Burkholderia pseudomallei. This disease is highly endemic in Northern Australia and South east Asia. Due to lack of experience and validated diagnostic modalities, this disease remains misdiagnosed or underdiagnosed, especially in areas of low endemicity. The disease spectrum may vary from mild skin infection without sepsis to disseminated infection and sepsis with case fatality ranging from 14% to 40%. Mortality associated with this disease may reach up to 80% if effective antimicrobial drugs are not given. [1] Clinical diagnosis is difficult as the disease has no pathognomonic clinical features and is "a remarkable imitator" of various infectious as well as noninfectious diseases. [2] A high incidence of melioidosis has been reported in people who have underlying predisposing conditions such as diabetes mellitus, renal disease, alcoholism, malnutrition, and people with immunosuppression. [3] For confirmation of clinical diagnosis, culture on a selective medium such as Ashdown's medium is still considered as gold standard. Culture has 100% specificity, but sensitivity may vary depending on the type of specimen, media used, and the expertise of the microbiologist. An oxidase-positive, Gram-negative bacilli showing bipolar staining exhibiting resistance to aminoglycosides, colistin and polymyxin but showing sensitivity to amoxyclav may be provisionally identified as B. pseudomallei in resource-poor laboratory settings. [4] Rapid identification from colonies can be done with latex agglutination assays utilizing monoclonal or polyclonal antibodies. Many such assays developed in-house have been described which are rapid, inexpensive, and accurate; however, they need to be validated first. [5] Various commercially available identification systems showing variable accuracy in identification are also available such as API 20NE, VITEK 2, and BD PHOENIX automated microbiology system, but there accuracy relies on the size of the strain database used for identification. Geographical location also needs to be taken into consideration as B. pseudomallei is known to harbor a vast intraspecies genomic diversity causing misdiagnosis in the automated system as concluded by the author in this study. Furthermore, these commercial systems may fail to distinguish between B. pseudomallei, Burkholderia thailandensis (phonotypically similar but rarely virulent species), and members of Burkholderia cepacia complex. [6] Molecular confirmation by polymerase chain reaction (PCR) based on type III secretion system gene and single-nucleotide polymorphism in conserved regions such as BurkDiff assay can be done in reference laboratories. 16S rRNA gene sequencing for the identification of bacteria can also be done. Newer rapid methods based on mass spectrometry, such as matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS), are found potentially useful in the correct identification of B. pseudomallei. Direct rapid detection from clinical specimen has been tried with immunofluorescence assay, lateral flow assay, and PCR. Various serological tests such as indirect hemagglutination assay and enzyme-linked immune sorbent assay have been utilized in various studies showing variable sensitivity and specificity. Recently, techniques such as metabolomic profiling with help of ultra high performance liquid chromatography-electrospray ionization-quadruple-time of flight-mass spectrometry (UHPLC-ESI-Q-TOF-MS) are also being researched for identification of B. pseudomallei from culture supernatants and distinguishing them from B. thailandensis and B. cepacia complex. [7] For antimicrobial susceptibility testing, Clinical and Laboratory Standard Institute recommends minimum inhibitory concentration (MIC) measurements, but disc diffusion susceptibility and E-test strips are commonly used in endemic regions. [8] Doubtful result of disc diffusion susceptibility test, especially for trimethoprim-sulfamethoxazole, should be confirmed by MIC method. Ceftazidime and amoxyclav have been used as empirical treatment for melioidosis, but in rare chances of nonresponsiveness, use of carbapenems is advocated. Antimicrobial drug susceptibility testing methods using quantitative PCR to rapidly evaluate susceptibility, by comparing the growth of bacteria exposed to varying concentration of antimicrobial drugs with that of unexposed bacteria, are being developed which will give result within 12 h. [1] A confirmed diagnosis of B. pseudomallei is a challenge, especially in low-prevalence settings. B. pseudomallei is a potential category B bioterrorism agent and a misdiagnosis can put the laboratory personnel at high risk of acquiring this infection by inhalation, inoculation, or ingestion. Documented reports of melioidosis from India are limited, which can be due to lack of awareness and nonavailability of good laboratory services in peripheral areas. [9] Therefore, clinicians and microbiologists should be made aware about this pathogen and its frequent misdiagnosis. Availability of validated diagnostic reagents for immunological and molecular tests and expansion of databases of commercial identification systems will likely remove the major hurdles in correct identification of B. pseudomallei. Development of rapid point of care tests such as lateral flow immunoassay would also prove to be helpful in rapid identification of isolates and direct detection from clinical specimens, especially in low-resource settings.
